Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Saved in:
| Title: | Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. |
|---|---|
| Authors: | Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain. mvmateos@usal.es., Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Facon T; CHU Lille Service Des Maladies du Sang, 59000, Lille, France., Auner HW; Imperial College London, London, UK., Leleu X; Department of Hematology, CHU La Miletrie and Inserm CIC 1402, Poitiers, France., Hájek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic., Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece., Delimpasi S; General Hospital Evangelismos, Athens, Greece., Simonova M; Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine., Špička I; Charles University and General Hospital, Prague, Czech Republic., Pour L; University Hospital Brno, Brno, Czech Republic., Kriachok I; National Cancer Institute, Kiev, Ukraine., Pylypenko H; Cherkassy Regional Oncological Center, Cherkassy, Ukraine., Doronin V; City Clinical Hospital #40, Moscow, Russian Federation., Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine., Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK., Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India., Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK., Stevens DA; Norton Cancer Institute, St. Matthews Campus, Louisville, KY, USA., Quach H; St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia., Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Moreau P; Hotel-Dieu, University Hospital, Nantes, France., Levy M; Baylor University Medical Center, Dallas, TX, USA., Badros AZ; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA., Anderson LD Jr; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, USA., Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy., Chai Y; Karyopharm Therapeutics Inc, Newton, MA, USA., Jeha J; Karyopharm Therapeutics Inc, Newton, MA, USA., Arazy M; Karyopharm Therapeutics Inc, Newton, MA, USA., Shah J; Karyopharm Therapeutics Inc, Newton, MA, USA., Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA., Kauffman MG; Karyopharm Therapeutics Inc, Newton, MA, USA., Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA., Grosicki S; Medical University of Silesia, Katowice, Poland. |
| Source: | Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 13; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2021 Apr 13. |
| Publication Type: | Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
